Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
3.700
+0.050 (1.37%)
Nov 18, 2025, 4:00 PM EST - Market closed
Pluri Revenue
Pluri had revenue of $316.00K in the quarter ending September 30, 2025, a decrease of -3.07%. This brings the company's revenue in the last twelve months to $1.33M, up 121.74% year-over-year. In the fiscal year ending June 30, 2025, Pluri had annual revenue of $1.34M with 309.82% growth.
Revenue (ttm)
$1.33M
Revenue Growth
+121.74%
P/S Ratio
19.88
Revenue / Employee
$9,338
Employees
142
Market Cap
31.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.34M | 1.01M | 309.82% |
| Jun 30, 2024 | 326.00K | 39.00K | 13.59% |
| Jun 30, 2023 | 287.00K | 53.00K | 22.65% |
| Jun 30, 2022 | 234.00K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PLUR News
- 6 months ago - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PRNewsWire
- 7 months ago - Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. - GlobeNewsWire
- 9 months ago - Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness - GlobeNewsWire
- 9 months ago - Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution - GlobeNewsWire
- 10 months ago - Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition - GlobeNewsWire
- 11 months ago - Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease - GlobeNewsWire
- 1 year ago - Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 1 year ago - BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PRNewsWire